Clinical Trial Update: The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias [Phase 2]

View source ↗

Summary

A Phase 2 trial of alemtuzumab for autoimmune cytopenias was terminated; the update discusses the study's efficacy and safety findings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Cytopenias

Drugs mentioned

• Alemtuzumab (Alemtuzumab)

Snippet

Sponsor: Phramongkutklao College of Medicine and Hospital | Conditions: Autoimmune Cytopenias | Phase 2 | Status: TERMINATED